Company & Sponsor Intelligence
Eisai Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting1
Completed3
Countries2
Therapeutic footprint
alzheimersepilepsyparkinsons
Indexed studies
NCT01240187A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects
epilepsy · United KingdomPHASE1
epilepsy · United KingdomPHASE1
NCT01327859Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia
parkinsons · United KingdomPHASE3
parkinsons · United KingdomPHASE3
NCT04015141A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
epilepsy · United StatesPHASE2
epilepsy · United StatesPHASE2
NCT01600859Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
alzheimers · United StatesPHASE1
alzheimers · United StatesPHASE1
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →